Saturday, June 24, 2017 1:40:30 AM
A scam? LOL…Lets discuss facts again.
Oncolix has a worldwide patent portfolio of over 30 patents for Prolanta.
Early funding for Prolanta came from the Susan G. Komen Foundation and the US government.
More recent funding has been in the form of accredited investors, endowments and trusts, like the family trust of Ernest Mario.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
Participants in these private offerings are likely investing in a royalty stake of future revenue when/if Prolanta goes to market.
Accredited investment often differs from PIPE financing that can be toxic or dilutive to current shareholders.
With the latest round of private offerings (from early 2017,) currently being completed, AEPP could continue clinical trials without any need to dilute.
BTW, People can just check out the ibox and sticky posts for accurate and current information to save everyone a lot of time.
IMO and FWIW.
Oncolix has a worldwide patent portfolio of over 30 patents for Prolanta.
Early funding for Prolanta came from the Susan G. Komen Foundation and the US government.
More recent funding has been in the form of accredited investors, endowments and trusts, like the family trust of Ernest Mario.
Ernest Mario served as Chief Executive Officer of Glaxo Holdings, plc, based out of London, England, known today as GlaxoSmithKline NYSE:GSK.
Ernest Mario was also the Chairman and CEO of Alza Corporation, based in Palo Alto, CA, from 1993 until the company was purchased by Johnson & Johnson, Inc, NYSE: JNJ in 2001.
Participants in these private offerings are likely investing in a royalty stake of future revenue when/if Prolanta goes to market.
Accredited investment often differs from PIPE financing that can be toxic or dilutive to current shareholders.
With the latest round of private offerings (from early 2017,) currently being completed, AEPP could continue clinical trials without any need to dilute.
BTW, People can just check out the ibox and sticky posts for accurate and current information to save everyone a lot of time.
IMO and FWIW.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
